View Older Stories View More Recent Stories

Nov 12, 2016 11:15AM Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
Nov 12, 2016 10:40AM Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma
Nov 10, 2016 05:00PM Bristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Nov 10, 2016 04:15PM Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annu
Nov 10, 2016 11:21AM Bristol-Myers Squibb (BMY), Johns Hopkins Enter New Immuno-Oncology Research Collaboration
Nov 10, 2016 11:19AM Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research
Nov 10, 2016 07:59AM Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016
Nov 10, 2016 07:00AM Bristol-Myers Squibb (BMY), Nitto Denko Enter siRNA Therapy Licensing Agreement
Nov 10, 2016 06:59AM Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
Nov 10, 2016 06:55AM Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study
Nov 9, 2016 08:31AM Bristol-Myers Squibb to Take Part in Stifel 2016 Health Care Conference
Nov 9, 2016 07:00AM Bristol-Myers Squibb (BMY), Infinity Pharma (INFI) Enter Advanced Solid Tumors-Focused Collaboration
Nov 9, 2016 06:59AM Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Advanced Solid Tumors
Nov 9, 2016 06:59AM Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors
Nov 3, 2016 09:10AM Bristol-Myers Squibb to Present New Data at the 58th Annual Meeting & Exposition of the American Society of Hematology Demonstrating Research Advancements in Immuno-Oncology and Across Multiple Bl
Nov 2, 2016 07:00AM Bristol-Myers Squibb (BMY) Announces Presentation of New Opdivo + Yervoy, Immuno-Oncology Data at 2016 STC
Nov 2, 2016 06:59AM New Data Presentations at SITC 2016 Annual Meeting Highlight Bristol-Myers Squibb’s Leadership in Advancing the Science of Immuno-Oncology Combinations
Nov 1, 2016 11:12AM Bristol-Myers Squibb to Take Part in Credit Suisse 2016 Health Care Conference
Oct 31, 2016 08:04AM Bristol-Myers Squibb (BMY) Announces Presentation of Opdivo Combo Data at SMR 2016 Congress
Oct 31, 2016 08:04AM New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in M
Oct 28, 2016 10:11AM Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade
Oct 27, 2016 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Oct 26, 2016 02:46PM Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
Oct 25, 2016 08:01AM Bristol-Myers Squibb (BMY) Announces New Data from Opdivo Phase 2 in cHL; ORR was 73% Across Subgroups
Oct 25, 2016 08:00AM New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients
Oct 24, 2016 06:59AM Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for Cancer Research
Oct 21, 2016 02:20PM Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Opdivo sBLA as Treatment for Adv. Bladder Cancer
Oct 21, 2016 02:19PM U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer
Oct 21, 2016 11:03AM Bristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter 2016 Results on October 27
Oct 17, 2016 12:15PM Bristol-Myers Squibb Foundation Joins White House Cancer Moonshot
Oct 14, 2016 07:01AM Bristol-Myers Squibb (BMY) Announces Receipt of Positive CHMP Opinion for Opdivo as r/r cHL Post-ASCT Treatment
Oct 14, 2016 06:59AM Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transpl
Oct 10, 2016 12:57PM Unusual 11 Mid-Day Movers 10/10: (EGAS) (MCUR) (TSRO) Higher; (TWTR) (TWLO) (MYGN) Lower
Oct 10, 2016 09:17AM Pre-Open Stock Movers 10/10: (IPCI) (TSRO) (MYL) Higher; (TWTR) (BMY) (DOV) Lower (more...)
Oct 10, 2016 06:59AM Bristol-Myers Squibb (BMY) Announces Strong Data from Yervoy Phase 3 vs. Placebo in Melanoma Patients
Oct 10, 2016 06:33AM Bristol-Myers Squibb (BMY) Presents Strong Data from Opdivo + Yervoy Combo Phase 1 in mRCC
Oct 10, 2016 06:26AM Bristol-Myers Squibb (BMY) Announces Statistically Significant Data from Opdivo Phase 3 in Squamous Cell Carcinoma
Oct 9, 2016 08:45AM Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer
Oct 9, 2016 07:46AM Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
Oct 9, 2016 07:30AM Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study
Oct 9, 2016 07:00AM Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
Oct 9, 2016 02:15AM Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advance
Oct 9, 2016 02:15AM Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study
Oct 8, 2016 03:09AM Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer
Oct 8, 2016 02:15AM Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study
Oct 3, 2016 05:13PM New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach
Sep 27, 2016 07:11AM Bristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Evaluate Opdivo + NKTR-214 Combo
Sep 27, 2016 06:59AM Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214
Sep 22, 2016 09:38AM Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference
Sep 20, 2016 07:07AM Bristol-Myers Squibb (BMY) Says EMA Validated Opdivo Type 2 Variation App for Bladder Cancer
View More Recent Stories View Older Stories